DALLAS, Nov. 4, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring MannKind Corp. (Nasdaq:MNKD). The report includes financial, comparative and investment analyses, and pertinent industry... [read full story]
|
RELATED
|
|
DALLAS -- InvestorSoup.com announces an investment report featuring MannKind Corp. . The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated...
VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD - News), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming...
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. - Imperial Capital’s 3rd Annual...
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. Imperial Capital's 3rd Annual Global...
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced...
Finance, Banking & Insurance, Investing & Markets, Pharmaceuticals, Ambulatory Health Care, Medicines & Remedies, Scientific Discoveries, Health Care, Cancers, Biopharmaceuticals, Investing, Cancer Therapy, Corporate Earnings, Corporate Performance, Medical Research, Gilead Sciences, Biogen, Genzyme
